PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation

详细信息    查看全文

• 作者：Xiaoyan Dou (1)
  Jing Wei (1)
  Aiqin Sun (1)
  Genbao Shao (1)
  Chandra Childress (2)
  Wannian Yang (1) (2)
  Qiong Lin (1) (2)
  
  1. School of Medical Sciences and Laboratory Medicine ; Jiangsu University ; 301 Xuefu Road ; Zhenjiang ; Jiangsu ; China
  2. Weis Center for Research ; Geisinger Clinic ; 100 N. Academy Avenue ; Danville ; PA17822 ; USA
  
• 关键词：Breast cancer ; Atorvastatin ; PBK/TOPK ; Geranylgeranylation ; YAP
• 刊名：Cancer Cell International
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：2,221 KB
• 参考文献：1. Gaudet, S, Branton, D, Lue, RA (2000) Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci U S A 97: pp. 5167-5172 CrossRef
  2. Komatsu, M, Yoshimaru, T, Matsuo, T, Kiyotani, K, Miyoshi, Y, Tanahashi, T (2013) Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol 42: pp. 478-506
  3. Shiraishi, T, Terada, N, Zeng, Y, Suyama, T, Luo, J, Trock, B (2011) Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 9: pp. 153 CrossRef
  4. Singh, PK, Srivastava, AK, Dalela, D, Rath, SK, Goel, MM, Bhatt, ML (2014) Expression of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma. Immunobiology 219: pp. 469-474 CrossRef
  5. Lei, B, Liu, S, Qi, W, Zhao, Y, Li, Y, Lin, N (2013) PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression. Histopathology 63: pp. 696-703
  6. Oh, SM, Zhu, F, Cho, YY, Lee, KW, Kang, BS, Kim, HG (2007) T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. Cancer Res 67: pp. 5186-5194 CrossRef
  7. Zhu, F, Zykova, TA, Kang, BS, Wang, Z, Ebeling, MC, Abe, Y (2007) Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology 133: pp. 219-231 CrossRef
  8. Hu, F, Gartenhaus, RB, Eichberg, D, Liu, Z, Fang, HB, Rapoport, AP (2010) PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene 29: pp. 5464-5474 CrossRef
  9. Shih, MC, Chen, JY, Wu, YC, Jan, YH, Yang, BM, Lu, PJ (2012) TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 31: pp. 2389-2400 CrossRef
  10. Park, JH, Lin, ML, Nishidate, T, Nakamura, Y, Katagiri, T (2006) PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 66: pp. 9186-9195 CrossRef
  11. Goldstein, JL, Brown, MS (1990) Regulation of the mevalonate pathway. Nature 343: pp. 425-430 CrossRef
  12. Duncan, RE, El-Sohemy, A, Archer, MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14: pp. 1897-1898 CrossRef
  13. Osmak, M (2012) Statins and cancer: current and future prospects. Cancer Lett 324: pp. 1-12 CrossRef
  14. Clendening, JW, Penn, LZ (2012) Targeting tumor cell metabolism with statins. Oncogene 31: pp. 4967-4978 CrossRef
  15. Liao, JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: pp. 285-288 CrossRef
  16. Mandal, CC, Ghosh-Choudhury, N, Yoneda, T, Choudhury, GG, Ghosh-Choudhury, N (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286: pp. 11314-11327 CrossRef
  17. Ghosh-Choudhury, N, Mandal, CC, Ghosh-Choudhury, N, Ghosh Choudhury, G (2010) Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 22: pp. 749-758 CrossRef
  18. Freed-Pastor, WA, Mizuno, H, Zhao, X, Langer酶d, A, Moon, SH, Rodriguez-Barrueco, R (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: pp. 244-258 CrossRef
  19. Zhao, B, Tumaneng, K, Guan, KL (2011) The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 13: pp. 877-883 CrossRef
  20. Zhao, B, Wei, X, Li, W, Udan, RS, Yang, Q, Kim, J (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: pp. 2747-2761 CrossRef
  21. Piccolo, S, Dupont, S, Cordenonsi, M (2014) The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 94: pp. 1287-1312 CrossRef
  22. Yu, FX, Guan, KL (2013) The Hippo pathway: regulators and regulations. Genes Dev 27: pp. 355-371 CrossRef
  23. Harvey, KF, Zhang, X, Thomas, DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13: pp. 246-257 CrossRef
  24. Lamar, JM, Stern, P, Liu, H, Schindler, JW, Jiang, ZG, Hynes, RO (2012) The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 109: pp. E2441-E2450 CrossRef
  25. Wang, X, Su, L, Ou, Q (2012) Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Euro J Cancer 48: pp. 1227-1234 CrossRef
  26. Pan, D (2010) The hippo signaling pathway in development and cancer. Dev Cell 19: pp. 491-505 CrossRef
  27. Dong, J, Feldmann, G, Huang, J, Wu, S, Zhang, N, Comerford, SA (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130: pp. 1120-1133 CrossRef
  28. Mi W, Lin Q, Childress C, Sudol M, Robishaw J, Berlot CH, et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene. 2014, in press.
  29. Wang, Z, Wu, Y, Wang, H, Zhang, Y, Mei, L, Fang, X (2014) Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A 111: pp. E89-E98 CrossRef
  30. Sorrentino, G, Ruggeri, N, Specchia, V, Cordenonsi, M, Mano, M, Dupont, S (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 16: pp. 357-366 CrossRef
  31. Fritz, G (2009) Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 9: pp. 626-638 CrossRef
  32. Yu, FX, Zhao, B, Panupinthu, N, Jewell, JL, Lian, I, Wang, LH (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150: pp. 780-791 CrossRef
  33. Fukukawa, C, Ueda, K, Nishidate, T, Katagiri, T, Nakamura, Y (2010) Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer 49: pp. 861-872 CrossRef
  34. Hu, F, Gartenhaus, RB, Zhao, XF, Fang, HB, Minkove, S, Poss, DE (2013) c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas. Leuk Res 37: pp. 447-454 CrossRef
  35. Nicolay, BN, Frolov, MV (2008) Context-dependent requirement for dE2F during oncogenic proliferation. PLoS Genet 4: pp. e1000205 CrossRef
  
• 刊物主题：Cancer Research; Cell Biology;
• 出版者：BioMed Central
• ISSN：1475-2867

文摘

PDZ binding-kinase (PBK) (also named T-lymphokine-activated killer cell-originated protein kinase (TOPK)), a serine/threonine kinase, is tightly controlled in normal tissues but elevated in many tumors, and functions in tumorigenesis and metastasis. However, the signaling that regulates expression of PBK in cancer cells remains elusive. Here we show that atorvastatin (Lipitor), an inhibitor of hydroxymethylglutaryl co-enzyme A (HMG-CoA) reductase that is a rate-limiting enzyme of mevalonate pathway, down-regulates expression of PBK by impairing protein geranylgeranylation. The shRNA knockdown demonstrated that Yes-associated protein (YAP) mediates geranylgeranylation-regulated expression of PBK. Importantly, atorvastatin or the geranylgeranyltransferase I inhibitor GGTI-298 inhibited breast cancer cell proliferation through inactivation of YAP signaling and down-regulation of PBK. These findings have defined a new signaling pathway that regulated expression of PBK and identified PBK as a downstream target of the Hippo-YAP signaling, uncoverd a mechanism underlying the anti-cancer effect by inhibition of mevalonate pathway and geranylgeranylation, and provided a potential target for breast cancer targeted therapy.